PF-08052666 was designed to address the limitations of earlier anti-MSLN ADCs through a novel antibody, differentiated linker ...

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

Dr. Brian Czerniecki, of Moffitt Cancer Center, led a CURE Educated Patient® Updates in Metastatic Breast Cancer event, and ...

PALO ALTO, CA, UNITED STATES, April 25, 2025 /EINPresswire.com/ -- Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors supports potential best-in-class profile. Data presented ...

ZW171 exhibits strong anti-tumor activity in patient derived xenograft (PDX) models of NSCLC and pancreatic cancer, and in ex-vivo patient-derived ovarian cancer organoids with endogenous ...

EQS-News: Pentixapharm Holding AG / Key word (s): Conference/Scientific publication Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 ...

Twelve months after revaccination, antibody levels declined but remained significantly higher than baseline in patients with CLL.

B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $5 from $7 and keeps a Buy rating on the shares. The firm cites PDS01 ...

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has been granted IND clearance by the FDA for its antibody-drug conjugate (ADC) drug SKB-518.